



9th September 2017

Document reference: UK/ABG/0005/17

Eperzan▼ (albiglutide): global discontinuation of medicine—do not initiate new patients; transition all current patients to an alternative therapy by July 2018

Dear Healthcare Professional,

GSK will discontinue the commercial sale and availability of Eperzan worldwide. Commercial supplies will no longer be available in the UK from July 2018.

Suggested Actions:

- 1: Initiate discussions with patients currently on Eperzan with a plan to transition all patients to an alternative therapy as appropriate by July 2018
- 2: Do not initiate treatment for any new patients
- 3: Ensure your practice team is aware of this information

This decision does not impact ongoing clinical studies for type 2 diabetes with Eperzan. A separate communication will be distributed to clinical trial investigators with specifics related to ongoing studies.

Background and further information

Eperzan▼ (albiglutide) subcutaneous injections (30 mg and 50 mg) have been licenced in the UK since 2014 for adults with type 2 diabetes mellitus.

This withdrawal is on commercial grounds only, and is not related to efficacy or safety of the medicine.

GSK has also communicated this decision to the EMA and the MHRA.

If you have any questions, contact the Customer Contact Centre, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT; customercontactuk@gsk.com; Freephone: 0800 221441.



For medical information enquiries please email ukmedinfo@gsk.com or call 0800 221 441 (option 4).

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Will Spencer'.

Dr Will Spencer MA (Cantab) MBBS MRCPCH MFPM
UK Medical Director IRDBU
Immunology, Diabetes and Rare Diseases Business Unit
GlaxoSmithKline

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

This letter is not a comprehensive description of the risks with the use of Eperzan. Please refer to the Summary of Product Characteristics available at <https://www.medicines.org.uk/emc/medicine/31399>

Trade marks are owned by or licensed to the GSK group of companies